HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 182 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,446,936 | -68.2% | 288,280 | -65.8% | 0.00% | -66.7% |
| Q2 2023 | $29,698,952 | +57.9% | 843,960 | +46.5% | 0.01% | +50.0% |
| Q1 2023 | $18,813,158 | +139.9% | 576,207 | +304.8% | 0.00% | +100.0% |
| Q4 2022 | $7,843,650 | -22.9% | 142,353 | -38.1% | 0.00% | 0.0% |
| Q3 2022 | $10,177,000 | +94.9% | 229,803 | +114.6% | 0.00% | +100.0% |
| Q2 2022 | $5,222,000 | -36.3% | 107,063 | -36.5% | 0.00% | -50.0% |
| Q1 2022 | $8,197,000 | +112.6% | 168,479 | +86.3% | 0.00% | +100.0% |
| Q4 2021 | $3,856,000 | +145.0% | 90,431 | +120.3% | 0.00% | – |
| Q3 2021 | $1,574,000 | +24.5% | 41,047 | -8.3% | 0.00% | – |
| Q2 2021 | $1,264,000 | -24.7% | 44,771 | -11.8% | 0.00% | – |
| Q1 2021 | $1,678,000 | +68.3% | 50,779 | +84.1% | 0.00% | – |
| Q4 2020 | $997,000 | -86.6% | 27,583 | -87.4% | 0.00% | -100.0% |
| Q3 2020 | $7,445,000 | – | 219,593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |